Provided by Tiger Trade Technology Pte. Ltd.

Jazz Pharmaceuticals PLC

172.19
+2.601.53%
Post-market: 172.190.00000.00%19:13 EST
Volume:1.31M
Turnover:224.51M
Market Cap:10.46B
PE:-28.43
High:172.46
Open:169.34
Low:168.56
Close:169.59
52wk High:182.99
52wk Low:95.49
Shares:60.77M
Float Shares:58.65M
Volume Ratio:1.91
T/O Rate:2.23%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.0558
EPS(LYR):8.65
ROE:-9.06%
ROA:4.88%
PB:2.64
PE(LYR):19.91

Loading ...

Earning Preview: Jazz Pharmaceuticals PLC revenue is expected to increase by 9.94%, institutions are predominantly bullish

Earnings Agent
·
Feb 17

BRIEF-UK's MHRA Approves Zanidatamab For Treatment Of Biliary Tract Cancer

Reuters
·
Feb 19

Jazz Pharmaceuticals Gets UK Approval for Biliary Tract Cancer Treatment

MT Newswires Live
·
Feb 19

UK's Mhra: Approves Zanidatamab (Ziihera) for the Treatment of Biliary Tract Cancer

THOMSON REUTERS
·
Feb 19

Jazz Pharmaceuticals to Participate in Major Investor Conferences

Reuters
·
Feb 18

Jazz Pharmaceuticals plc announces upcoming financial results webcast

Reuters
·
Feb 11

ALX Oncology Reports CD47 Biomarker Predicts Response to Evorpacept in Advanced HER2-Positive Breast Cancer

Reuters
·
Jan 30

Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (PVLA), Nurix Therapeutics (NRIX) and Jazz Pharmaceuticals (JAZZ)

TIPRANKS
·
Jan 29

Jazz Pharmaceuticals Plc : TD Cowen Raises Target Price to $220 From $205

THOMSON REUTERS
·
Jan 29

Analysts Have Conflicting Sentiments on These Healthcare Companies: Jazz Pharmaceuticals (JAZZ) and AbbVie (ABBV)

TIPRANKS
·
Jan 16

Analysts Offer Insights on Healthcare Companies: Privia Health Group (PRVA), Jazz Pharmaceuticals (JAZZ) and Annexon Biosciences (ANNX)

TIPRANKS
·
Jan 16

Jazz Pharmaceuticals Showcases Rare Disease Breakthroughs and Growth Strategy in New Presentation

Reuters
·
Jan 14

Jazz Pharmaceuticals (JAZZ) Gets a Buy from Jefferies

TIPRANKS
·
Jan 13

BRIEF-Jazz Pharmaceuticals PLC - Expects To Meet 2025 Revenue Guidance - SEC Filing

Reuters
·
Jan 12

Jazz Pharmaceuticals Plc - Expects to Meet 2025 Revenue Guidance - SEC Filing

THOMSON REUTERS
·
Jan 12

Jazz Pharmaceuticals Completes Acquisition of Chimerix

Reuters
·
Jan 12

Jazz Pharmaceuticals price target raised to $235 from $210 at Needham

TIPRANKS
·
Jan 12

Truist Raises Price Target on Jazz Pharmaceuticals to $230 From $220, Keeps Buy Rating

MT Newswires Live
·
Jan 12

Boehringer Ingelheim: Phase 1B Study to Evaluate Combination of Zongertinib and Zanidatamab in Her2-Positive Breast Cancer Patients

THOMSON REUTERS
·
Jan 12

Jazz Pharmaceuticals Is Maintained at Buy by Needham

Dow Jones
·
Jan 12